SUBSCRIBE
SUBSCRIBE
News   Drug Development

Phynova Obtains FDA Approval Of Its IND To Enter Into A Clinical Trial Of PYN17 For The Treatment Of Chronic Hepatitis C

January 8, 2007 | 
1 min read
Phynova Group PLC (AIM: PYN), a developer of pharmaceuticals derived from Chinese botanical drugs targeting viral and metabolic diseases and cancer, is pleased to announce the introduction of its first drug candidate into clinical trials in the US.
Clinical research Phase I Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
IN PARTNERSHIP WITH ELEMENT
Pharma Faces Investor Woes and Tariff Threats, Turns to AI and Collaboration for Survival
November 3, 2025
 · 
5 min read
 · 
BioSpace Insights
Pictured: uniQure headquarters in Amsterdam
Huntington’s disease
FDA Does ‘About-Face’ on UniQure’s Huntington’s Gene Therapy
November 3, 2025
 · 
3 min read
 · 
Heather McKenzie
Futuristic Cyber Abstracy Eye Background 4K
Deals
4DMT Sends Eye Disease Asset’s Asia Rights to Otsuka for $85M Upfront
October 31, 2025
 · 
1 min read
 · 
Annalee Armstrong
Eli Lilly's biotechnology center in California
Pain
Lilly Refines Pain Pipeline Again, Scrapping Mid-Stage Program
October 31, 2025
 · 
2 min read
 · 
Tristan Manalac